MDS Professional Report
Activity Overview
Episode publication activity over the past year
Episodes
Pathogenesis and inflammaging in MDS [MDS Professional Report]
01 Feb 2025
Contributed by Lukas
Dr. Moshe Mittelman is hosting the world-leading expert Dr. Michael Savona and they have an attractive conversation on several mechanisms involved i...
Treatment of lower-risk MDS [MDS Professional Report]
15 Dec 2024
Contributed by Lukas
Prof. Uwe Platzbecker from Leipzig and Prof. Moshe Mittelman from Tel-Aviv in an interesting conversation on the various available therapeutic modalit...
Treatment for Higher-risk MDS [MDS Professional Report]
01 Dec 2024
Contributed by Lukas
Prof. Nicolaus Kröger from Hamburg and Prof. Moshe Mittelman from Tel-Aviv, in a stimulating conversation on the various therapeutic modalities, incl...
Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]
27 May 2024
Contributed by Lukas
Dr. Nicolaos Papadantonakis from Emory Atlanta and Dr. Moshe Mittelman from Tel-Aviv, describe several updated abstracts from 2023 ASH with a special ...
New trials to address the anemia of lower-risk MDS [MDS Professional Report]
27 Mar 2024
Contributed by Lukas
Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of Hematology (...
Transfusions and quality of life [MDS Professional Report]
01 May 2023
Contributed by Lukas
Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss issues related to RBC transfusions, the hemoglobin threshold for tr...
Bone marrow failure disorders in childhood [MDS Professional Report]
05 Dec 2022
Contributed by Lukas
Prof. Akiko Shimamura of Harvard Medical School, Boston, a world known expert of pediatric hematology discusses with Prof. Guillermo Sanz ,of Valencia...
The role of genetics in MDS management [MDS Professional Report]
28 Sep 2022
Contributed by Lukas
Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, follow up and ...
MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]
06 Feb 2022
Contributed by Lukas
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and DroritMerkel, of the Sheba Medical Center, both from Tel Aviv University, Israel,di...
Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report]
22 Sep 2021
Contributed by Lukas
Chien Aza – Pembro - BJHThe combination of azacitidine and pembrolizumab may be a potential effective regimen for patients with higher-risk MDS and ...
Will Venetoclax Become The New Standard? [MDS Professional Report]
02 Jun 2021
Contributed by Lukas
We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk myelodyspl...
Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report]
30 Mar 2021
Contributed by Lukas
PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic ...
TP53 mutations – were they born equal [MDS Professional Report]
25 Feb 2021
Contributed by Lukas
Bernard E et al: In the first presented study, Dr. Elza Bernard and colleagues deliver an important lesson about the high-risk mutation TP53. That is:...